Regeneron Pharmaceuticals, Inc.

Frank Kuhnert

Thomas Nittoli

Michael Van Meter

Caroline Liot

The disclosure relates to methods for treating or inhibiting the growth of a tumor, wherein the methods include selecting and administering to a subject in need thereof a therapeutically effective amount of an IL-4/IL-13 pathway inhibitor and a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor. In certain embodiments, the IL-4/IL-13 pathway inhibitor enhances the anti-tumor efficacy of PD-1 blockade.

IL-4/IL-13 pathway inhibitors for enhanced efficacy in treating cancer

The present disclosure provides antibody-drug conjugates comprising anti-PTCRA antibodies and methods of using the same. The ADCs of the disclosure are useful for the treatment of T-ALL and other disorders related to elevated expression of PTCRA.

Growing community of inventors

Cortlandt Manor, NY, United States of America

Frank Kuhnert